663 related articles for article (PubMed ID: 20215541)
81. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
[TBL] [Abstract][Full Text] [Related]
82. Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6.
Raponi M; Kralovicova J; Copson E; Divina P; Eccles D; Johnson P; Baralle D; Vorechovsky I
Hum Mutat; 2011 Apr; 32(4):436-44. PubMed ID: 21309043
[TBL] [Abstract][Full Text] [Related]
83. Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling.
Pensabene M; Spagnoletti I; Capuano I; Condello C; Pepe S; Contegiacomo A; Lombardi G; Bevilacqua G; Caligo MA
Ann Oncol; 2009 May; 20(5):874-8. PubMed ID: 19179552
[TBL] [Abstract][Full Text] [Related]
84. Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
Hum Mutat; 2019 Dec; 40(12):2296-2317. PubMed ID: 31343793
[TBL] [Abstract][Full Text] [Related]
85. Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary.
Whiley PJ; Guidugli L; Walker LC; Healey S; Thompson BA; Lakhani SR; Da Silva LM; ; Tavtigian SV; Goldgar DE; Brown MA; Couch FJ; Spurdle AB
Hum Mutat; 2011 Jun; 32(6):678-87. PubMed ID: 21394826
[TBL] [Abstract][Full Text] [Related]
86. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
[TBL] [Abstract][Full Text] [Related]
87. BRCA1/2 missense mutations and the value of in-silico analyses.
Sadowski CE; Kohlstedt D; Meisel C; Keller K; Becker K; Mackenroth L; Rump A; Schröck E; Wimberger P; Kast K
Eur J Med Genet; 2017 Nov; 60(11):572-577. PubMed ID: 28807866
[TBL] [Abstract][Full Text] [Related]
88. Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.
Balz V; Prisack HB; Bier H; Bojar H
Cancer Genet Cytogenet; 2002 Oct; 138(2):120-7. PubMed ID: 12505256
[TBL] [Abstract][Full Text] [Related]
89. Characterization of common BRCA1 and BRCA2 variants.
Deffenbaugh AM; Frank TS; Hoffman M; Cannon-Albright L; Neuhausen SL
Genet Test; 2002; 6(2):119-21. PubMed ID: 12215251
[TBL] [Abstract][Full Text] [Related]
90. Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer.
Davy G; Rousselin A; Goardon N; Castéra L; Harter V; Legros A; Muller E; Fouillet R; Brault B; Smirnova AS; Lemoine F; de la Grange P; Guillaud-Bataille M; Caux-Moncoutier V; Houdayer C; Bonnet F; Blanc-Fournier C; Gaildrat P; Frebourg T; Martins A; Vaur D; Krieger S
Eur J Hum Genet; 2017 Oct; 25(10):1147-1154. PubMed ID: 28905878
[TBL] [Abstract][Full Text] [Related]
91. BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
Mundhofir FE; Wulandari CE; Prajoko YW; Winarni TI
Asian Pac J Cancer Prev; 2016; 17(3):1539-46. PubMed ID: 27039803
[TBL] [Abstract][Full Text] [Related]
92. BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy.
Anczuków O; Buisson M; Léoné M; Coutanson C; Lasset C; Calender A; Sinilnikova OM; Mazoyer S
Clin Cancer Res; 2012 Sep; 18(18):4903-9. PubMed ID: 22753590
[TBL] [Abstract][Full Text] [Related]
93. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
Baert A; Machackova E; Coene I; Cremin C; Turner K; Portigal-Todd C; Asrat MJ; Nuk J; Mindlin A; Young S; MacMillan A; Van Maerken T; Trbusek M; McKinnon W; Wood ME; Foulkes WD; Santamariña M; de la Hoya M; Foretova L; Poppe B; Vral A; Rosseel T; De Leeneer K; Vega A; Claes KBM
Hum Mutat; 2018 Apr; 39(4):515-526. PubMed ID: 29280214
[TBL] [Abstract][Full Text] [Related]
94. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
Meaney-Delman D; Bellcross CA
Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
[TBL] [Abstract][Full Text] [Related]
95. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
Toland AE; Andreassen PR
J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
[TBL] [Abstract][Full Text] [Related]
96. Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer.
Jasiak A; Koczkowska M; Stukan M; Wydra D; Biernat W; Izycka-Swieszewska E; Buczkowski K; Eccles MR; Walker L; Wasag B; Ratajska M
Exp Mol Pathol; 2023 Apr; 130():104856. PubMed ID: 36791903
[TBL] [Abstract][Full Text] [Related]
97. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
[TBL] [Abstract][Full Text] [Related]
98. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
Lovelock PK; Healey S; Au W; Sum EY; Tesoriero A; Wong EM; Hinson S; Brinkworth R; Bekessy A; Diez O; Izatt L; Solomon E; Jenkins M; Renard H; Hopper J; Waring P; Tavtigian SV; Goldgar D; Lindeman GJ; Visvader JE; Couch FJ; Henderson BR; Southey M; Chenevix-Trench G; Spurdle AB; Brown MA;
J Med Genet; 2006 Jan; 43(1):74-83. PubMed ID: 15923272
[TBL] [Abstract][Full Text] [Related]
99. In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
Rodríguez-Balada M; Roig B; Martorell L; Melé M; Salvat M; Vilella E; Borràs J; Gumà J
Cancer Genet; 2016 Nov; 209(11):487-492. PubMed ID: 27886673
[TBL] [Abstract][Full Text] [Related]
100. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
Gómez García EB; Oosterwijk JC; Timmermans M; van Asperen CJ; Hogervorst FB; Hoogerbrugge N; Oldenburg R; Verhoef S; Dommering CJ; Ausems MG; van Os TA; van der Hout AH; Ligtenberg M; van den Ouweland A; van der Luijt RB; Wijnen JT; Gille JJ; Lindsey PJ; Devilee P; Blok MJ; Vreeswijk MP
Breast Cancer Res; 2009; 11(1):R8. PubMed ID: 19200354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
